Viking Fund Management LLC Trims Stock Position in Eli Lilly and Company $LLY

Viking Fund Management LLC decreased its position in Eli Lilly and Company (NYSE:LLY) by 24.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,300 shares of the company’s stock after selling 2,700 shares during the period. Viking Fund Management LLC’s holdings in Eli Lilly and Company were worth $8,920,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of LLY. 10Elms LLP grew its position in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after buying an additional 10 shares in the last quarter. Bridgewater Advisors Inc. grew its holdings in Eli Lilly and Company by 0.3% during the 3rd quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company’s stock worth $3,018,000 after acquiring an additional 11 shares in the last quarter. Manske Wealth Management increased its position in Eli Lilly and Company by 2.5% during the 3rd quarter. Manske Wealth Management now owns 448 shares of the company’s stock valued at $342,000 after purchasing an additional 11 shares during the period. Guardian Partners Inc. increased its position in Eli Lilly and Company by 0.3% during the 3rd quarter. Guardian Partners Inc. now owns 4,000 shares of the company’s stock valued at $3,302,000 after purchasing an additional 12 shares during the period. Finally, Strategic Investment Solutions Inc. IL raised its holdings in shares of Eli Lilly and Company by 1.6% in the 3rd quarter. Strategic Investment Solutions Inc. IL now owns 741 shares of the company’s stock valued at $565,000 after purchasing an additional 12 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 performance and outlook praised — analysts highlight a strong quarterly beat and leadership across GLP‑1 franchises, reinforcing Lilly’s growth trajectory and guidance. Firing on All Cylinders: Eli Lilly (NYSE:LLY) Q4 Earnings Lead the Way
• Positive Sentiment: Brokerage sentiment remains constructive — coverage aggregates to an average “Moderate Buy,” supporting demand from institutional investors. Eli Lilly and Company (NYSE:LLY) Receives Average Rating of “Moderate Buy” from Brokerages
• Positive Sentiment: Analyst model tweaks are slightly upward — Erste Group nudged its FY‑2026 EPS estimate higher, consistent with consensus revisions as GLP‑1 sales ramp. (Research note referenced).
• Positive Sentiment: Investor pieces highlight long‑term upside from GLP‑1 dominance — bullish commentary (e.g., The Motley Fool) fuels retail/investor enthusiasm around growth durability. Could Buying Eli Lilly Today Set You Up for Life?
• Neutral Sentiment: M&A speculation in the sector (MDGL buyout rumors) is driving headlines — that lifts some small‑cap peers but is only speculative for Lilly unless confirmed. MDGL stock surges most in a month on Eli Lilly buyout speculation
• Neutral Sentiment: Comparative analyst pieces (LLY vs ABBV) keep focus on relative upside and risks across big pharma, but they don’t change Lilly’s core fundamentals immediately. LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?
• Negative Sentiment: Regulatory and societal scrutiny of GLP‑1s is rising (coverage on “societal obligation” and access/ethical debates) — this could increase political/regulatory risk and pressure sentiment if policy responses accelerate. Eli Lilly and the ‘societal obligation’ of GLP-1s

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Guggenheim increased their price objective on shares of Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Barclays started coverage on Eli Lilly and Company in a research note on Thursday, February 19th. They set an “overweight” rating and a $1,350.00 price objective for the company. BMO Capital Markets reiterated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Finally, Jefferies Financial Group set a $1,300.00 price target on shares of Eli Lilly and Company and gave the company a “buy” rating in a report on Friday, March 13th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,221.44.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $898.68 on Friday. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The company has a market cap of $849.09 billion, a PE ratio of 39.16, a P/E/G ratio of 1.06 and a beta of 0.40. The business has a 50-day simple moving average of $1,010.46 and a two-hundred day simple moving average of $960.96. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.